Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31M Sell
493,096
-275,200
-36% -$19.2M ﹤0.01% 2135
2025
Q4
$51M Buy
768,296
+108,796
+16% +$7.03M 0.01% 1608
2025
Q3
$44.4M Buy
659,500
+297,300
+82% +$23.5M 0.01% 1756
2025
Q2
$31.6M Sell
362,200
-74,000
-17% -$5.8M 0.01% 1924
2025
Q1
$29.8M Buy
436,200
+82,600
+23% +$6.74M 0.01% 1959
2024
Q4
$27.5M Sell
353,600
-80,400
-19% -$5.95M 0.01% 1995
2024
Q3
$29.1M Buy
434,000
+188,740
+77% +$15.5M 0.01% 1546
2024
Q2
$27.8M Buy
245,260
+7,600
+3% +$961K 0.01% 1423
2024
Q1
$33M Buy
237,660
+54,700
+30% +$6.88M 0.01% 1329
2023
Q4
$22.7M Sell
182,960
-181,240
-50% -$18.5M 0.01% 1511
2023
Q3
$34M Buy
364,200
+172,800
+90% +$19.5M 0.01% 1096
2023
Q2
$24.6M Buy
191,400
+120,500
+170% +$14.6M 0.01% 1293
2023
Q1
$8.24M Sell
70,900
-26,522
-27% -$2.97M ﹤0.01% 2051
2022
Q4
$11M Buy
+97,422
New +$10.7M ﹤0.01% 1847
2015
Q3
Sell
-26,800
Closed -$536K 8453
2015
Q2
$536K Buy
+26,800
New +$471K ﹤0.01% 4065
2015
Q1
Sell
-400
Closed -$6K 8934
2014
Q4
$6K Buy
+400
New +$4.9K ﹤0.01% 8820

Other funds holding DXCM

UBS Group's DXCM Position: Q1 2026 in Review

UBS Group increased its DexCom (DXCM) stake by 126% in Q1 2026, buying an estimated $169M and bringing the position to 4,349,959 shares worth $273M. The position accounts for 0.04% of the portfolio, ranked #471.

UBS Group first reported a position in DXCM in Q4 2014 and has held it in 46 quarters since. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • UBS Group held 4,349,959 shares of DexCom worth $273M as of Q1 2026.
  • UBS Group bought 2,426,179 DexCom shares in Q1 2026, an estimated $169M.
  • DexCom made up 0.04% of UBS Group's portfolio in Q1 2026, its #471 holding.
  • UBS Group first reported a position in DexCom in Q4 2014 and has held it in 46 quarters since.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.